Cart
sales@molnova.com
Ro-3201195
CAS No. 249937-52-8
Ro-3201195( —— )
Catalog No. M36218 CAS No. 249937-52-8
Ro-3201195 is a novel orally available p38 MAPK inhibitor with high selectivity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 329 | In Stock |
|
| 5MG | 304 | In Stock |
|
| 10MG | 456 | In Stock |
|
| 25MG | 747 | In Stock |
|
| 50MG | 1004 | In Stock |
|
| 100MG | 1376 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 2753 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRo-3201195
-
NoteResearch use only, not for human use.
-
Brief DescriptionRo-3201195 is a novel orally available p38 MAPK inhibitor with high selectivity.
-
DescriptionRo-3201195 is a novel orally available p38 MAPK inhibitor with high selectivity.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
Recptorp38 MAPK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number249937-52-8
-
Formula Weight371.36
-
Molecular FormulaC19H18FN3O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESNC=1N(N=CC1C(=O)C2=CC(OCC(CO)O)=CC=C2)C3=CC=C(F)C=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Darizmetinib
Darizmetinib (HRX215, HRX-0215) is an MKK4 inhibitor. Inhibition of MKK4 leads to enhancement of the MKK7 and JNK1 signaling pathways, thereby activating the transcription factors ATF2 and ELK1, promoting cell proliferation and liver regeneration.
-
MW181 hydrochloride
MW181 (MW01-10-181SRM) is an isoform-selective, brain-permeable, and orally bioavailable small molecule inhibitor of p38α MAPK with Ki of 184 nM.
-
AZD-7624
AZD-7624 is a potent, selective, inhaled p38α MAPK inhibitor with pIC50 of 10.0.
